跳转至内容
Merck

228M-1

Sigma-Aldrich

BG8, LewisY (F3) Mouse Monoclonal Antibody

登录查看公司和协议定价


About This Item

分類程式碼代碼:
12352203
NACRES:
NA.41

生物源

mouse

品質等級

100
500

共軛

unconjugated

抗體表格

culture supernatant

抗體產品種類

primary antibodies

無性繁殖

F3, monoclonal

描述

For In Vitro Diagnostic Use in Select Regions (See Chart)

形狀

buffered aqueous solution

物種活性

human

包裝

vial of 0.1 mL concentrate (228M-14)
vial of 0.5 mL concentrate (228M-15)
bottle of 1.0 mL predilute (228M-17)
vial of 1.0 mL concentrate (228M-16)
bottle of 7.0 mL predilute (228M-18)

製造商/商標名

Cell Marque

技術

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:10-1:50

同型

IgM

控制

adenocarcinoma of lung

運輸包裝

wet ice

儲存溫度

2-8°C

視覺化

cytoplasmic

基因資訊

human ... F3(2152)

一般說明

Blood group antigens have been examined as potential discriminators between pulmonary adenocarcinoma (PACA) and epithelioid mesothelioma (EM). Lewisy is the only one of these that appears to have some merit. BG8 is raised from the SK-LU-3 lung cancer line and its ability to distinguish between PACA and EM was first reported by Jordon and colleagues in 1989. Three groups have since reported their results. These studies included 231 cases of PACA and 197 cases of EM. Sensitivity and specificity for PACA were both 93%. Yaziji H et al. reported a sensitivity of nonmesothelial antigens for adenocarcinoma as organ dependent, with BG8 performing at 98% in the breast cancer group, and 100% in the lung cancer group. The specificity of the nonmesothelial (non-EM) antigens for adenocarcinoma was 98% for BG8. They concluded using logical regression analysis that a three-antibody immunohistochemical panel including calretinin, BG8, and MOC-31 would provide 96% sensitivity and specificity for distinguishing EM from adenocarcinoma from a variety of sources (lung, ovary, breast, stomach).

品質


IVD

IVD

IVD

RUO

聯結

BG8 Positive Control Slides, Product No. 228S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

外觀

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

準備報告

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

其他說明

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

法律資訊

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our 产品选型工具.


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Alberto M Marchevsky et al.
Applied immunohistochemistry & molecular morphology : AIMM, 15(2), 140-144 (2007-05-26)
There are no firmly established guidelines for the use of antibodies in immunohistology as individual tests or panels. Practicing pathologists must rely on information available in individual publications, review articles, books, and internet-based databases to develop diagnostic immunohistochemical algorithms for
J E King et al.
Histopathology, 48(3), 223-232 (2006-01-25)
Immunohistochemistry is frequently employed to aid the distinction between mesothelioma and pulmonary adenocarcinoma metastatic to the pleura, but there is uncertainty as to which antibodies are most useful. We analysed published data in order to establish sensitivity and specificity of
N G Ordóñez
The American journal of surgical pathology, 24(4), 598-606 (2000-04-11)
The distinction between malignant pleural mesotheliomas and adenocarcinomas, particularly those originating in the lung, is a difficult diagnostic problem that can be facilitated by the use of immunohistochemical markers. In this study, the immunoreactivity of thyroid transcription factor-1 (TTF-1), E-cadherin
B Davidson et al.
Virchows Archiv : an international journal of pathology, 435(1), 43-49 (1999-08-04)
The detection of malignant cells in pleural, peritoneal, and pericardial fluids of cancer patients marks the presence of metastatic disease and is associated with a grave prognosis. We evaluated five epithelial markers for the detection of cancer cells in 94
Nelson G Ordóñez
The American journal of surgical pathology, 27(8), 1031-1051 (2003-07-29)
A large number of immunohistochemical markers that can facilitate the distinction between epithelioid pleural mesotheliomas and pulmonary peripheral adenocarcinomas have recently become available. The aim of this study is to compare the value of these new markers with others that

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门